Saltar al contenido
Merck
  • Downregulated lncRNA-SNHG1 enhances autophagy and prevents cell death through the miR-221/222 /p27/mTOR pathway in Parkinson's disease.

Downregulated lncRNA-SNHG1 enhances autophagy and prevents cell death through the miR-221/222 /p27/mTOR pathway in Parkinson's disease.

Experimental cell research (2019-09-10)
Chen Qian, Yongyi Ye, Hengxu Mao, Longping Yao, Xiang Sun, Baoyan Wang, Hongbo Zhang, Linghai Xie, Huan Zhang, Yizhou Zhang, Shizhong Zhang, Xiaozheng He
RESUMEN

Autophagy has been shown to be critically associated with the central mechanisms underlying Parkinson's disease (PD), while the mechanisms contributing to the imbalance of autophagy remain unclear. Small nucleolar RNA host gene 1 (SNHG1), a well-studied long noncoding RNA, has been reported to be significantly increased in PD. The potential biological functions of SNHG1 in the regulation of neuronal autophagy and cell death in PD, however, have not yet been completely elucidated. In this study, we examined the existence of regulatory networks involving SNHG1, the miR-221/222 cluster and the cyclin-dependent kinase inhibitor 1B (CDKN1B/p27)/mammalian target of rapamycin (mTOR) signaling pathway in PD. We observed that SNHG1 expression was gradually upregulated in PD cellular and animal models. Furthermore, silencing SNHG1 promoted autophagy and prevented MPP+-induced cell death, similar to the overexpression of the miR-221/222 cluster. Mechanistically, SNHG1 competitively binds to the miR-221/222 cluster and indirectly regulates the expression of p27/mTOR. In conclusion, these results demonstrated that downregulation of SNHG1 attenuated MPP+-induced decreases in LC3-II (an autophagic marker) levels and cytotoxicity through the miR-221/222/p27/mTOR pathway, suggesting that SNHG1 may be a therapeutic target for neuroprotection and disease treatment in PD.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Citrate Solution, pH ~3.0, 30 mM